Top

Published in:

01-12-2016 | What's New in Intensive Care

Should we take into account ESBLs in empirical antibiotic treatment?

Authors: Bassetti Matteo, Jesús Rodríguez Baño

Published in: Intensive Care Medicine | Issue 12/2016

Excerpt

Gram-negative bacteria (GNB) are increasingly multidrug-resistant and represent a growing problem in critically ill patients who are particularly prone to infection. One of the most important resistance mechanisms of GNB are β-lactamases conferring resistance to β-lactam antibiotics by hydrolysation of their β-lactam ring [1]. Of the many different β-lactamases, ESBLs comprise the largest group of enzymes [1], causing resistance to various β-lactam antibiotics including third-generation cephalosporins and monobactams, but not carbapenems. Even in areas hitherto known for having minor resistance problems, 5–10 % of patients hospitalized in ICU wards on a given day harbour ESBL-producing Enterobacteriaceae in their gut flora [2]. Plasmids encoding ESBLs easily spread among Enterobacteriaceae, mainly Escherichia coli and Klebsiella pneumoniae [3]. …

Gazin M, Paasch F, Goossens H, Malhotra-Kumar S, Mosar WP, Teams SWS (2012) Current trends in culture-based and molecular detection of extended-spectrum-beta-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 50(4):1140–1146 CrossRefPubMedPubMedCentral

Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C (2012) Clinical impact and risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38(11):1769–1778CrossRefPubMed

Jacoby GA, Munoz-Price LS (2005) The new beta-lactamases. N Engl J Med 352(4):380–391CrossRefPubMed

Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D (2013) A review of 10 years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals 6(11):1335–1346CrossRefPubMedPubMedCentral

European Centre for Disease Prevention and Control (2015) Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-NET). ECDC, Stockholm

Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78(4):443–448CrossRefPubMed

Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50(2):498–504CrossRefPubMedPubMedCentral

Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950CrossRef

Poulakou G, Bassetti M, Timsit JF (2016) Critically ill migrants with infection: diagnostic considerations for intensive care physicians in Europe. Intensive Care Med 42(2):245–248CrossRefPubMed

10.

Rodriguez-Bano J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C et al (2015) Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Y Microbiol Clin 33(5):337.e1–337.e21 CrossRef

11.

Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC et al (2007) Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 13(8):1144–1149CrossRefPubMedPubMedCentral

12.

Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S et al (2016) Colonization and infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother 71(4):1088–1097CrossRefPubMed

13.

Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH et al (2016) A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum beta-lactamase-producing organism. Clin Infect Dis Off Publ Infect Dis Soc Am 63(7):896–903CrossRefPubMed

14.

Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martinez-Martinez L et al (2016) Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother 71(6):1672–1680CrossRefPubMed

15.

Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H et al (2007) Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 59(2):277–284CrossRefPubMed

16.

Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B et al (2016) A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60(7):4159–4169CrossRefPubMed

Title: Should we take into account ESBLs in empirical antibiotic treatment?
Authors: Bassetti Matteo
Jesús Rodríguez Baño
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 12/2016
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-016-4599-6

At a glance: The STEP trials

Springer Medicine

Should we take into account ESBLs in empirical antibiotic treatment?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2016

Tardive tachypnea

The effect of sepsis and its inflammatory response on mechanical clot characteristics: a prospective observational study

Understanding why resistant bacteria are associated with higher mortality in ICU patients

Common femoral artery pseudoaneurysm

Factors affecting biomarkers of endothelial and alveolar epithelial dysfunction: response to comments by Kyo et al.

Understanding clinical signs of poor tissue perfusion during septic shock